{"id":"NCT02114931","sponsor":"Amgen","briefTitle":"Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis","officialTitle":"An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2016-04","completion":"2016-04","firstPosted":"2014-04-15","resultsPosted":"2017-04-24","lastUpdate":"2017-04-24"},"enrollment":467,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"BIOLOGICAL","name":"ABP 501","otherNames":["AMJEVITAâ„¢","Adalimumab-atto"]}],"arms":[{"label":"ABP 501","type":"EXPERIMENTAL"}],"summary":"The purpose of this open-label study is to evaluate the long-term safety and efficacy of ABP 501 in adults with moderate to severe rheumatoid arthritis (RA).","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"From the first dose of study drug in the extension study to 28 days following the last dose; 72 weeks","effectByArm":[{"arm":"ABP 501/ABP 501","deltaMin":143,"sd":null},{"arm":"Adalimumab/ABP 501","deltaMin":154,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":77,"countries":["United States","Bulgaria","Canada","Czechia","Germany","Hungary","Poland","Romania","Russia","Spain","United Kingdom"]},"refs":{"pmids":["33263165","30922373"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":229},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Bronchitis","Rheumatoid arthritis","Hypertension"]}}